Irvine Scientific ships first products from plant in Tokyo

Published: 24-Aug-2011
Packaging Pharmaceutical

Facility produces animal component-free cell culture media

Irvine Scientific has shipped the first products from its industrial cell culture media production facility in Tokyo to customers in Japan and Asia.

The new facility, located in Saitama prefecture, manufactures animal component-free cell culture media in volume requirements ranging from research use to production of biopharmaceuticals and vaccines. The plant has been commissioned and validated as completely animal component free (ACF).

The new facility, which meets the highest quality cGMP standards, currently occupies 1,720m2 and replicates the production and processes used at the Irvine Scientific’s Santa Ana, CA, US manufacturing facility.

The Tokyo site has state-of-the-art formulation and packaging equipment, and uses continuous milling and blending equipment designed and built to Irvine Scientific specifications. There is room for expansion depending on customer demands.

The Tokyo facility capacity doubles Irvine Scientific’s current powder manufacturing capability at Santa Ana and will bring the total capacity at both sites to more than 1.2 million kilos a year.

Irvine Scientific, a member of JX Holdings group, is a designer, manufacturer and distributor of industrial cell culture, cytogenetic, assisted reproductive technology (ART) and specialist media products. It is a large-scale producer of advanced quality cell culture media for the industrial bioprocess, medical, and diagnostic markets.

See more

You may also like

Design & Build

Fujifilm Irvine Scientific plans Netherlands manufacturing facility

Read more
Dry powder media, liquid media, and downstream bioprocessing liquids will all come out of this new plant

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Embracing sustainable change through labelling choice Paavo Sillanpää, Senior Manager, Ecosystem Pharma and Healthcare, EMEIA, UPM Adhesive Materials, discusses the latest trends in pharmaceutical packaging and labelling and how producers can embrace future-focused solutions and sustainable options without compromising performance
  3. Efficient extraction of proteins from bacterial cells SoluLyse from Amsbio is a bacterial protein extraction reagent that provides a highly efficient yet gentle method for extracting soluble proteins from bacterial cells
  4. Polpharma Biologics announces US launch of Tyruko, the first FDA-approved natalizumab biosimilar for MS Tyruko is now available to US patients with multiple sclerosis and Crohn’s disease, expanding access to a more affordable biologic option
  5. BioDuro appoints Yaohui Ji as Global President, CMC to accelerate expansion of integrated CRDMO capabilities BioDuro, a trusted global Contract Research, Development, and Manufacturing Organization (CRDMO), announced the appointment of Mr. Yaohui Ji as Global President, CMC

You may also like

Design & Build

Fujifilm Irvine Scientific plans Netherlands manufacturing facility

Dry powder media, liquid media, and downstream bioprocessing liquids will all come out of this new plant
Ingredients

Irvine introduces NK cell expansion medium for immunotherapy and translational research applications

The first chemically defined, animal component-free cell culture medium for natural killer (NK) cells
Manufacturing

Fujifilm completes acquisition of Irvine Scientific Sales Company and IS Japan

With the acquisition of ISUS and ISJ, Fujifilm will now be able to provide a broad product portfolio from biopharmaceuticals to <i>in vitro</i> fertilisation and cell therapy
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Embracing sustainable change through labelling choice

Paavo Sillanpää, Senior Manager, Ecosystem Pharma and Healthcare, EMEIA, UPM Adhesive Materials, discusses the latest trends in pharmaceutical packaging and labelling and how producers can embrace future-focused solutions and sustainable options without compromising performance
Pharmaceutical

Polpharma Biologics announces US launch of Tyruko, the first FDA-approved natalizumab biosimilar for MS

Tyruko is now available to US patients with multiple sclerosis and Crohn’s disease, expanding access to a more affordable biologic option
Research & Development

Samsung Epis launches subsidiary Epis NexLab for next-gen biotech platform development

Epis NexLab will focus on transforming highly scalable peptide-related technologies into development platforms for the discovery of new drug candidates, including license-out or joint development with global pharmaceutical companies
Analysis

Efficient extraction of proteins from bacterial cells

SoluLyse from Amsbio is a bacterial protein extraction reagent that provides a highly efficient yet gentle method for extracting soluble proteins from bacterial cells
Subscribe now